Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Medshine Discovery Inc.

Xiangjian Wang

Xiquan Zhang

Xin Tian

Ling Yang

Xunqiang Wang

Kai Zhou

Kevin X Chen

Hongjiang Xu

Zhongmin Maxwell Wang

Yu Xia

Baiyong Li

Shanchun Wang

Rong Li

Boyu Hu

Yanxin Yu

Linghui Wu

Zheng Liu

Hai Jiang

Zhongnan Xu

Wenjun Geng

Peng Lv

Xiaoyuan Chen

Jiangfeng Lin

Haomin Chen

Hua Zhong

Baohui Han

Tianqing Chu

Peng Lyu

Xiaoping Jin

Chen Shen

The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.

Therapeutic combination of quinoline derivative and antibody

The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor. Specifically, the present invention relates to use of quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer, 

Quinoline derivative for treatment of triple-negative breast cancer

A bicyclic compound acting as a ROR&#x3b3; inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR&#x3b3; inhibitory activities, being expected to be used for treating diseases mediated by ROR&#x3b3; receptors in a mammal. 

Bicylic compound acting as an inhibitor

Provided in the present invention are a use of quinoline derivatives for treating oesophageal cancer and a treatment method, a pharmaceutical composition and a kit thereof. The 1-[[[4-(4-fluoro-2-methyl-1H-indole-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine provided by the present invention can effectively treat oesophageal cancer, and reduce the sum of the diameters of patient's target lesions.

Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof

Growing community of inventors

Lianyungang, China

Xiangjian Wang